Leerink analyst David Larsen raised his price target for Diplomat Pharmacy to $33 after hosting investor meetings with management. The analyst believes demand for Diplomat's pharmacy benefits manager CastiaRx is accelerating relative to previous years. Further, he thinks earnings potential from biosimilars, over the long run, may be greater than what he had been expecting. In addition, Larsen is "positively surprised" that the senior leadership team does not view President Trump's Blueprint plan as a significant risk. The analyst reiterates an Outperform rating on Diplomat Pharmacy.